Emavusertib: Difference between revisions

Emavusertib
	File:Emavusertib structure.png
Identifiers
	IUPAC name N-[5-[(3R)-3-hydroxypyrrolidin-1-yl]-2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide;
CAS Number	1801344-14-8;
PubChem CID	118224491;
Chemical and physical data
Formula	C24H25N7O5
Molar mass	491.508 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NC=CC(=C1)C2=NC(=CO2)C(=O)NC3=CC4=C(N=C3N5CC[C@H](C5)O)N=C(O4)N6CCOCC6;
	InChI InChI=1S/C24H25N7O5/c1-14-10-15(2-4-25-14)23-27-18(13-35-23)22(33)26-17-11-19-20(28-21(17)31-5-3-16(32)12-31)29-24(36-19)30-6-8-34-9-7-30/h2,4,10-11,13,16,32H,3,5-9,12H2,1H3,(H,26,33)/t16-/m1/s1; Key:SJHNWSAWWOAWJH-MRXNPFEDSA-N;

Content deleted Content added

Inline

Revision as of 02:11, 12 June 2024

Emavusertib (CA-4948) is a drug which acts as a selective inhibitor of the enzyme Interleukin-1 receptor-associated kinase 4 (IRAK-4) and was developed for the treatment of some forms of cancer.^[1]^[2]^[3]

^ Gummadi VR, Boruah A, Ainan BR, Vare BR, Manda S, Gondle HP, Kumar SN, Mukherjee S, Gore ST, Krishnamurthy NR, Marappan S, Nayak SS, Nellore K, Balasubramanian WR, Bhumireddy A, Giri S, Gopinath S, Samiulla DS, Daginakatte G, Basavaraju A, Chelur S, Eswarappa R, Belliappa C, Subramanya HS, Booher RN, Ramachandra M, Samajdar S. Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies. ACS Med Chem Lett. 2020 Oct 14;11(12):2374-2381. doi:10.1021/acsmedchemlett.0c00255 PMID 33335659
^ Von Roemeling CA, Doonan BP, Klippel K, Schultz D, Hoang-Minh L, Trivedi V, Li C, Russell RA, Kanumuri RS, Sharma A, Tun HW, Mitchell DA. Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases. Clin Cancer Res. 2023 May 1;29(9):1751-1762. doi:10.1158/1078-0432.CCR-22-1682 PMID 36749885
^ Parrondo RD, Iqbal M, Von Roemeling R, Von Roemeling C, Tun HW. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies. Front Immunol. 2023 Oct 26;14:1239082. doi:10.3389/fimmu.2023.1239082 PMID 37954584

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.